DIFFERENTIATED ANTIBIOTICS.
MULTIPLE INDICATIONS.

A key gap in the recently approved drugs, as well as those in late-stage pipeline, is the lack of oral options that cover Gram-Negative and Gram-Positive bacterial infections. An intravenous and oral drug product will address the treatment of Gram-Negative and Gram-Positive infections implied in HABP/VABP, CABP, uUTI, cUTI, and other enteric infections. In essence, a replacement for fluroquinolones.

GYROX-1

Intravenous for Critical care infections Phase 1

Pre-clinical

Coverage:

  • Critical priority pathogens including Acinetobacter baumannii & Pseudomonas aeruginosa
  • High priority pathogens including Enterococcus faecium, Staphylococcus aureus and Campylobacter sp.
  • Bio-threat pathogens including Bacillus anthracis, Yersinia pestis, Francisella tularensis, Burkholderia mallei, Burkholderia pseudomallei

GYROX-2

Oral for Hospital & community infections Phase 1

Late Lead

Coverage:

  • Critical priority pathogens including Enterobacteriaceae, Acinetobacter baumannii & Pseudomonas aeruginosa
  • High priority pathogens including Enterococcus faecium, Staphylococcus aureus, Campylobacter sp., Streptococcus pneumoniae

GYROX-3

Oral for Cystic fibrosis patients Phase 1

Early Lead

Coverage:

  • Critical priority pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, Burkholderia cepacia species complex, Stenotrophomonas maltophilia, Achromobacter spp.